Two medicines, side by side
Caspofungin vs voriconazole
Caspofungin and voriconazole are both labeled for fungal infections. Drugs@FDA records approvals of caspofungin since 2001 and of voriconazole since 2002. In FDA's classes, caspofungin is an echinocandin antifungal and voriconazole an azole antifungal.
Check it at the source: the caspofungin FDA label on DailyMed (effective October 11, 2024); the voriconazole FDA label on DailyMed (effective February 26, 2026).
Highlights of the caspofungin record
Caspofungin (Cancidas) · label of October 11, 2024
Used for
From the label: indicationsCANCIDAS is an echinocandin antifungal indicated in adults and pediatric patients (3 months of age and older) for: Empirical therapy for presumed fungal infections in febrile, neutropenic patients. ( 1 ) Treatment of candidemia and the following Candida infections: intra-abdominal abscesses, peritonitis and pleural space infections. ( 1 ) Treatment of esophageal candidiasis. […]
On the market
- Earliest approval on file
- January 26, 2001
- Generic labelers
- 5 labelers
- Pharmacy cost
- Not in the survey
Supply and safety
- Shortage
- A presentation being discontinued
- Recalls
- 0
Highlights of the voriconazole record
Voriconazole (Vfend) · label of February 26, 2026
Used for
From the label: indicationsVFEND is an azole antifungal indicated for the treatment of adults and pediatric patients 2 years of age and older with: • Invasive aspergillosis ( 1.1 ) • Candidemia in non-neutropenics and other deep tissue Candida infections ( 1.2 ) • Esophageal candidiasis ( 1.3 ) • Serious fungal infections caused by Scedosporium apiospermum and Fusarium species including Fusarium solani, in patients intolerant of, or […]
On the market
- Earliest approval on file
- May 24, 2002
- Generic labelers
- 31 labelers
- Pharmacy cost
- $1.88 per tablet
Supply and safety
- Shortage
- A presentation being discontinued
- Recalls
- 4
Source: FDA drug labels via openFDA (Caspofungin label of October 11, 2024, Voriconazole label of February 26, 2026); NDC Directory, Drugs@FDA, NADAC, FDA shortages and recalls (October 8, 2026)
How do caspofungin and voriconazole differ on the record?
In FDA's classes, caspofungin is an echinocandin antifungal and voriconazole an azole antifungal.
How each works, in its label's words: Caspofungin, “Caspofungin is an echinocandin antifungal drug [see Microbiology (12.4) ].”; Voriconazole, “Voriconazole is an antifungal drug [see Microbiology (12.4) ].”
Generics: caspofungin since 2017; voriconazole since 2010 (Drugs@FDA).
| Caspofungin | Voriconazole | |
|---|---|---|
| Labeled for | Fungal infections | Fungal infections |
| Pharmacologic class | Echinocandin Antifungal | Azole Antifungal |
| How it works (label) | Caspofungin is an echinocandin antifungal drug [see Microbiology (12.4) ]. | Voriconazole is an antifungal drug [see Microbiology (12.4) ]. |
| Half-life (label) | A short α-phase occurs immediately postinfusion, followed by a β-phase (half-life of 9 to 11 hours) that characterizes much of the profile and exhibits clear log-linear behavior from 6 to 48 hours postdose during which … | n/a |
| Earliest approval on file (Drugs@FDA) | January 26, 2001 | May 24, 2002 |
| First generic approved | September 29, 2017 | April 22, 2010 |
| Generic labelers (NDC) | 5 labelers | 31 labelers |
| Pharmacy cost (NADAC, each one's most listed form; strengths differ) | n/a | $1.88 per tablet (Voriconazole 200 mg tablet) |
| 12-month price change | n/a | -2% |
| Boxed warning | No | No |
| Shortage now | A presentation being discontinued | A presentation being discontinued |
| Recalls recorded | 0 | 4 |
| FAERS reports (a report is not proof of cause; counts follow how widely a medicine is used) | 4,684 | 30,201 |
| DEA schedule | none | none |
Source: Drugs@FDA, FDA NDC Directory, CMS NADAC of October 7, 2026, FDA shortages and recalls, FAERS via openFDA (FDA files October 8, 2026)
What next?
- Alternatives to caspofungin
- every medicine labeled for the same conditions